The Impact of Interventions to Treat Incident Diabetes on Circulating microRNAs in the Diabetes Prevention Program

糖尿病预防计划中治疗糖尿病的干预措施对循环 microRNA 的影响

基本信息

  • 批准号:
    10545053
  • 负责人:
  • 金额:
    $ 52.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-02 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Circulating MicroRNAs Associated with Intensive Lifestyle Intervention and Metformin in the Diabetes Prevention Program Cohort Project summary Type 2 diabetes is priority for both public health and precision medicine. The etiology of type 2 diabetes is complex and both genetic and lifestyle/environmental factors contribute to risk. Current approaches to risk prediction and risk reduction are limited because they fail to account for the interactions between biological and lifestyle risk factors. MicroRNAs regulate expression of genes in response to lifestyle factors and capture the combined effects of genetic predisposition and the environment. Extracellular circulating microRNAs, which are readily detectable in blood, are emerging as useful indicators of disease etiology and show changes in response to the environment and behaviors. Our own prior studies and others have provided preliminary information about microRNAs as predictive biomarkers for incident type 2 diabetes and responses to risk reduction interventions. We showed that circulating microRNAs are associated with risk for type 2 diabetes, response to an insulin sensitizing pharmacologic agent, and lifestyle interventions (e.g., yoga, physical activity). Prior studies have been primarily cross-sectional in nature and were not powered to evaluate clusters of microRNAs as predictive markers. This study will determine whether microRNAs predict incident type 2 diabetes and whether there are interactions with risk reduction interventions. We will measure microRNAs in a subset of plasma samples banked at the NIDDK biorespository from participants in the completed NIH-funded Diabetes Prevention Program (DPP) trial that tested the effect of metformin, intensive lifestyle intervention, and placebo on risk for type 2 diabetes. This trial showed intensive lifestyle intervention decreased incidence of type 2 diabetes by 58% and metformin by 31% compared to placebo. The existing phenotypic data and biologic specimens from the DPP trial provide an exceptional opportunity to evaluate the relationships between longitudinal changes in both microRNAs and risk for type 2 diabetes in an extremely well characterized sample of individuals who underwent interventions that decreased incidence of type 2 diabetes. Circulating microRNAs will be measured using a flow cytometry- based direct detection assay that is compatible with heparin, the anticoagulant used for sample collection in the DPP trial. This study will be the first to evaluate, in a large, rigorously conducted clinical trial, microRNAs, singularly and as clusters, as predictors of type 2 diabetes and interactions with risk reduction interventions. This will also be the first study to model longitudinal trajectories of microRNAs and fasting blood glucose over time. This knowledge will improve our understanding of inter-individual variability in risk prediction, optimization of risk reduction interventions, and mechanisms for type 2 diabetes and responses to risk reduction interventions.
循环microrna与强化生活方式干预和二甲双胍在糖尿病中的作用

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Review of databases for experimentally validated human microRNA-mRNA interactions.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elena Flowers其他文献

Elena Flowers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elena Flowers', 18)}}的其他基金

Mentorship of Individuals from Historically Under-Represented Groups in Health Sciences Research
对健康科学研究中历史上代表性不足的群体的个人进行指导
  • 批准号:
    10794080
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
Empirically Based Career Development Program for Historically Under-Represented Early Career Trainees Supported by NIDDK
NIDDK 支持的针对历史上代表性不足的早期职业学员的基于经验的职业发展计划
  • 批准号:
    10746352
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
Exploratory Analysis of the Functional Implications of MicroRNAs Associated with Incident Type 2 Diabetes and Related Risk Factors.
与 2 型糖尿病事件及相关危险因素相关的 MicroRNA 功能意义的探索性分析。
  • 批准号:
    10404815
  • 财政年份:
    2020
  • 资助金额:
    $ 52.36万
  • 项目类别:
The Impact of Interventions to Treat Incident Diabetes on Circulating microRNAs in the Diabetes Prevention Program
糖尿病预防计划中治疗糖尿病的干预措施对循环 microRNA 的影响
  • 批准号:
    10337277
  • 财政年份:
    2020
  • 资助金额:
    $ 52.36万
  • 项目类别:
The Impact of Interventions to Treat Incident Diabetes on Circulating microRNAs in the Diabetes Prevention Program
糖尿病预防计划中治疗糖尿病的干预措施对循环 microRNA 的影响
  • 批准号:
    10502867
  • 财政年份:
    2020
  • 资助金额:
    $ 52.36万
  • 项目类别:
Evaluating Longitudinal Relationships Between Circulating MicroRNAs and Risk for Type 2 Diabetes and Responses to Behavioral Interventions
评估循环 MicroRNA 与 2 型糖尿病风险和行为干预反应之间的纵向关系
  • 批准号:
    9975150
  • 财政年份:
    2018
  • 资助金额:
    $ 52.36万
  • 项目类别:

相似海外基金

EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
  • 批准号:
    479295
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
  • 批准号:
    10629057
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
  • 批准号:
    23K06906
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
  • 批准号:
    10605482
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
  • 批准号:
    10559071
  • 财政年份:
    2023
  • 资助金额:
    $ 52.36万
  • 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
  • 批准号:
    22K07388
  • 财政年份:
    2022
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
  • 批准号:
    10536789
  • 财政年份:
    2022
  • 资助金额:
    $ 52.36万
  • 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
  • 批准号:
    22K06743
  • 财政年份:
    2022
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
  • 批准号:
    461790
  • 财政年份:
    2022
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
  • 批准号:
    474475
  • 财政年份:
    2022
  • 资助金额:
    $ 52.36万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了